Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA)-Multicenter Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

560 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-31

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aspergillus-specific IgG assays for the diagnosis of chronic pulmonary aspergillosis (CPA)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis

NCT03093220

Respiratory Infections Genetic Disorder Community-Acquired Infections +1 more

UNKNOWN

Community-Acquired Pneumonia Diagnosis Through Integrating Novel Microbiological Techniques.

NCT06259110

Community-acquired Pneumonia

NOT_YET_RECRUITING

Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate

NCT04358419

Aspergillosis Pneumonia Pneumocystis Pneumonia

COMPLETED

Multicenter Epidemiologic Study of Severe Community Acquired Pneumonia in China

NCT03728816

Community-acquired Pneumonia

UNKNOWN

Prospective Observational Trial of IAPA

NCT04530799

Influenza With Pneumonia Pulmonary Aspergillosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

chronic pulmonary aspergillosis (CPA) is one of the most refractory pulmonary infectious diseases, and the incidence is increased rapidly in recent years. Serum detection of Aspergillus-specific IgG is considered to be the most reliable method for diagnosing CPA, however, there is no formal report on the appropriate cut-off value for Aspergillus-specific IgG assay in Chinese patients. This study aimed to establish the datum.

Besides aspergillus-specific IgG, there are two other specific antibodies IgM and IgA. IgM is associated with the acute phase of an infection and IgA is associated with mucosal immunity. Their diagnostic values in CPA are still not clear. Meanwhile, whether detection of antibody levels in bronchoalveolar lavage fluid (BALF) could be useful in diagnosis of CPA has not been investigated. In this study, the serum and BALF levels of IgG, IgM and IgA would be detected simultaneously by the commercial available kits.

The investigators will establish the cut-off values of three antibodies by proven CPA patients and negative controls. Then, the cut-off values will be assessed in participants who have a suspected CPA, and the sensitivity, specificity, positive and negative predict value of the antibodies assays will be compared with that of standard diagnostic methods.

After performing the above diagnostic tests, CPA could be diagnosed more accurately and rapidly, so that the antifungal therapy could be evaluated more correctly and timely.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Pulmonary Aspergillosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

18 years to 85 years Lesions presented as cavity, nodule，mass or "destroyed lung" caused by fibrosis in CT imaging

Exclusion Criteria

* seriously immunocompromised patients

1. Recent history of neutropenia (\<0.5 × 109neutrophils/L \[\<500 neutrophils/mm3\] for\>10 days) temporally related to the onset of fungal disease
2. Receipt of an allogeneic stem cell transplant
3. Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for \>3 weeks
4. Treatment with other recognized T cell immunosuppressants, such as cyclosporine, TNF-a blockers, specific monoclonal antibodies (such as alemtuzumab), or nucleoside analogues during the past 90 days
5. Inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency)
* antifungal drug use within 3 months of screening
* dropout
* Pregnancy or lactation
* no inform consent

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes